Victor Biton

Summary

Affiliation: University of Texas
Country: USA

Publications

  1. ncbi Topiramate titration and tolerability
    V Biton
    Arkansas Epilepsy Program, Little Rock 72205, USA
    Ann Pharmacother 35:173-9. 2001
  2. ncbi Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial
    Victor Biton
    Arkansas Epilepsy Program, Little Rock 72205, USA
    J Child Neurol 18:133-9. 2003
  3. ncbi Zonisamide: newer antiepileptic agent with multiple mechanisms of action
    Victor Biton
    Two Lile Court, Suite 100, Little Rock, AR 72205, USA
    Expert Rev Neurother 4:935-43. 2004
  4. doi Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, AR 72205, USA
    Epilepsy Behav 19:352-8. 2010
  5. ncbi Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, Arkansas 77025, USA
    Epilepsia 49:418-24. 2008
  6. ncbi Clinical pharmacology and mechanism of action of zonisamide
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, AR, USA
    Clin Neuropharmacol 30:230-40. 2007
  7. ncbi Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, AR, USA
    Expert Opin Drug Metab Toxicol 2:1009-18. 2006
  8. ncbi Weight change and antiepileptic drugs: health issues and criteria for appropriate selection of an antiepileptic agent
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, Arkansas 72205, USA
    Neurologist 12:163-7. 2006
  9. doi Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, AR 72205, USA
    Clin Drug Investig 33:359-64. 2013
  10. doi Lacosamide for the treatment of partial-onset seizures
    Victor Biton
    Arkansas Epilepsy Program, 2 Lile Court Ste 100, Little Rock, AR 72205, USA
    Expert Rev Neurother 12:645-55. 2012

Detail Information

Publications19

  1. ncbi Topiramate titration and tolerability
    V Biton
    Arkansas Epilepsy Program, Little Rock 72205, USA
    Ann Pharmacother 35:173-9. 2001
    ..To evaluate the tolerability and efficacy of two titration rates for topiramate initiated as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalization, in a multicenter, double-blindtrial...
  2. ncbi Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial
    Victor Biton
    Arkansas Epilepsy Program, Little Rock 72205, USA
    J Child Neurol 18:133-9. 2003
    ..Whereas weight remained stable in adolescents treated with lamotrigine, weight increased in those treated with valproate by week 10 of this study and continued to increase at the end of the study...
  3. ncbi Zonisamide: newer antiepileptic agent with multiple mechanisms of action
    Victor Biton
    Two Lile Court, Suite 100, Little Rock, AR 72205, USA
    Expert Rev Neurother 4:935-43. 2004
    ..A review of the chemical properties, pharmacokinetics, metabolism, potential mechanisms of action, efficacy in seizure and nonseizure disorders, and tolerability was therefore thought to be timely...
  4. doi Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, AR 72205, USA
    Epilepsy Behav 19:352-8. 2010
    ..Significant separation from placebo for ≥50% reduction in PGTC seizures was observed beginning on treatment day 8. The most common adverse event was headache (lamotrigine XR 14%, placebo 16%)...
  5. ncbi Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, Arkansas 77025, USA
    Epilepsia 49:418-24. 2008
    ..This multicenter, double-blind, double-dummy, randomized, inpatient trial evaluated the safety, tolerability, and pharmacokinetics of intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures...
  6. ncbi Clinical pharmacology and mechanism of action of zonisamide
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, AR, USA
    Clin Neuropharmacol 30:230-40. 2007
    ....
  7. ncbi Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, AR, USA
    Expert Opin Drug Metab Toxicol 2:1009-18. 2006
    ..The pharmacokinetic, toxicology and safety profiles of lamotrigine make the drug suitable for use across a spectrum of patients with epilepsy...
  8. ncbi Weight change and antiepileptic drugs: health issues and criteria for appropriate selection of an antiepileptic agent
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, Arkansas 72205, USA
    Neurologist 12:163-7. 2006
    ..Weight change, either gain or loss, is a common AED side effect, conferring multiple risks of additional morbidity...
  9. doi Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, AR 72205, USA
    Clin Drug Investig 33:359-64. 2013
    ....
  10. doi Lacosamide for the treatment of partial-onset seizures
    Victor Biton
    Arkansas Epilepsy Program, 2 Lile Court Ste 100, Little Rock, AR 72205, USA
    Expert Rev Neurother 12:645-55. 2012
    ..LCM is available in tablets and an intravenous formulation when oral administration is temporarily not feasible...
  11. doi A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, Arkansas 72205, USA
    Epilepsia 52:234-42. 2011
    ..Efficacy and safety of adjunctive rufinamide (3,200 mg/day) was assessed in adolescents and adults with inadequately controlled partial-onset seizures receiving maintenance therapy with up to three antiepileptic drugs (AEDs)...
  12. ncbi Topiramate in patients with juvenile myoclonic epilepsy
    Victor Biton
    Arkansas Epilepsy Program, Little Rock 72205, USA
    Arch Neurol 62:1705-8. 2005
    ..Juvenile myoclonic epilepsy is one of the most common idiopathic generalized epilepsies, with most patients experiencing PGTCS...
  13. doi Lacosamide for the treatment of diabetic neuropathic pain
    Victor Biton
    Arkansas Epilepsy Program, Little Rock, AR 72205, USA
    Expert Rev Neurother 8:1649-60. 2008
    ..The pharmacokinetic properties of lacosamide include a fast rate of absorption, little or no interaction with cytochrome P450 isoenzymes, limited effect of age and gender on plasma levels and low potential for drug-drug interactions...
  14. ncbi Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy
    Victor Biton
    Arkansas Epilepsy Program, 2 Lile Court, Suite 100, Little Rock, AR 72205, USA
    CNS Drugs 17:781-91. 2003
    ..The most appropriate therapeutic choice is a weight-neutral medication unless circumstances dictate otherwise...
  15. ncbi Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures
    Elinor Ben-Menachem
    Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Epilepsia 48:1308-17. 2007
    ....
  16. ncbi A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy
    Mark E Sale
    Pharmacokinetic Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NC, USA
    Epilepsy Behav 6:63-70. 2005
    ....
  17. ncbi Divalproex-ER pharmacokinetics in older children and adolescents
    Sandeep Dutta
    Abbott Laboratories, Abbott Park, Illinois, USA
    Pediatr Neurol 30:330-7. 2004
    ....
  18. ncbi Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study
    Richard L Rauck
    The Center for Clinical Research, Winston Salem, NC, USA
    Clin J Pain 23:150-8. 2007
    ..Peripheral diabetic neuropathy affects between 20% and 45% of patients with diabetes...
  19. ncbi Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trials
    Ilo E Leppik
    MINCEP Epilepsy Care and University of Minnesota, 5775 Wayzata Boulevard, Suite 255, Minneapolis, MN 55416, USA
    Epilepsia 44:1585-7. 2003
    ..To determine the effect of levetiracetam (LEV) on partial seizure subtypes (simple partial, complex partial, and secondarily generalized seizures) in patients with refractory epilepsy...